About this trial
A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies. The new frontier in biomedical research is represented by organoids, a three-dimensional cell culture system obtained from a tissue fragment that accurately reproduces the essential properties of the original tissue in vitro, which could provide a valuable model for explanation of ovarian cancers pathogenesis and will allow to predict the response to a specific therapy. With this research project, we expect to generate ovarian cancer organoids to characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules).
Eligibility criteria
Qualifiers
Age > 18 years
Age < 80 years
Serous ovarian carcinoma
FIGO Stage III-IV
Disqualifiers
Ongoing or suspended immunosuppressive therapy within the last 6 months
Congenital or acquired immunodeficiency
Immunosuppressive state
Administration of chemotherapy for another neoplasm in the past 12 months
Trial design
Treatments tested in this trial
- Ovarian Cancer Organoids